Psilocybin: Clinical Trials

265 trials of Psilocybin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

97 recruiting, 77 completed, 27 active not recruiting, 25 not yet recruiting. 139 Phase 2, 100 Phase 1, 20 Early Phase 1, 11 Not applicable, 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2139Recruiting 52, Completed 33, Not yet recruiting 18, Active not recruiting 13, Unknown 13, Withdrawn 7, Suspended 2, Terminated 1
Phase 1100Completed 35, Recruiting 35, Active not recruiting 10, Not yet recruiting 9, Terminated 5, Unknown 3, Withdrawn 3
Early Phase 120Recruiting 11, Completed 4, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1
Not applicable11Completed 7, Enrolling by invitation 1, Recruiting 1, Unknown 1, Withdrawn 1
Phase 310Recruiting 5, Active not recruiting 3, Completed 2

Follow Psilocybin: new trials by email Literature Review of Psilocybin trials Research Report on Psilocybin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety Profile of Psilocybin for Cocaine Use Disorder
Psilocybin - Cocaine Use Disorder
Early Phase 1SuspendedUniversity of California, Los Angeles102029-02-012026-04-07
Psilocybin After Trauma Surgery for Pain
Psilocybin (Usona Institute), Postoperative analgesia - Pain Management, Postoperative Pain
Phase 1Not yet recruitingTrent Emerick702027-12-312026-08-06
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Psilocybin - Opioid Use Disorder
Phase 2WithdrawnJohns Hopkins University2027-04-012026-02-23
The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin
0mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 1mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 5mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink - Psilocybin Intoxication
Phase 1Not yet recruitingJohns Hopkins University802027-03-012026-10-16
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
Psilocybin - Treatment Resistant Depression, Substance Use Disorders
Phase 1 / Phase 2Not yet recruitingIndiana University502027-02-012026-10-23
Psilocybin for Methamphetamine Use Disorder
Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions). - Methamphetamine Use Disorder
Phase 2Not yet recruitingPeter Hendricks422027-02-012026-09-21
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
Psilocybin, Saline Placebo, Clonidine - Well-Being, Psychological, Psychedelic Experiences
Phase 1Not yet recruitingUniversity of Wisconsin, Madison1202027-02-012026-10-30
Psilocybin FCR Early-Stage Breast Cancer
Psilocybin 25 mg, Psilocybin 5 mg - Early-stage Breast Cancer, Fear of Cancer Recurrence
Phase 2Not yet recruitingNYU Langone Health1002027-01-022026-11-02
Psilocybin for Depression in Veterans
Psilocybin, modafinil, zolpidem - Major Depression
Phase 2Not yet recruitingVA Office of Research and Development1502027-01-012026-10-26
Group PACBT for Depression
Psilocybin (drug), Group Cognitive Behavioral Therapy - Depression - Major Depressive Disorder, Psilocybin
Phase 2Not yet recruitingUniversity of California, Los Angeles302027-01-012026-05-04
Effects of Psilocybin on Craving in Nicotine Dependence
Psilocybin (drug) - Nicotine Dependence
Phase 2Not yet recruitingUniversity of British Columbia32027-01-012026-10-01
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
Transcranial Magnetic Stimulation, Psilocybin (drug), Neurofeedback - PTSD, PTSD - Post Traumatic Stress Disorder
Phase 2Not yet recruitingUniversity of New Mexico1502026-12-312026-10-30
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
Biospecimen Collection, Functional Magnetic Resonance Imaging, Interview - Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Phase 2Not yet recruitingRoswell Park Cancer Institute202026-12-152026-11-05
Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain
Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg - Chronic Low Back Pain (CLBP), Physical Therapy
Phase 2Not yet recruitingYale University482026-12-012026-10-26
ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder
Psilocybin, Psilocybin-Assisted Therapy With Dialectical Behavior Therapy - Borderline Personality Disorder, Borderline Personality Pathology
Phase 1Not yet recruitingUniversity of Minnesota182026-12-012026-09-22
Psilocybin Therapy for Methamphetamine Use Disorder and HIV
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Phase 2RecruitingNicky Mehtani, MD, MPH302026-12-012026-11-09
The Effects of Psilocybin on Social Connectedness
Psilocybin, Placebo - Loneliness, Grief
Phase 1Not yet recruitingYale University512026-12-012026-11-12
Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy
Psilocybin 25mg, Music-centered psilocybin-assisted therapy, Mindfulness-centered psilocybin-assisted therapy - Treatment-Resistant Major Depressive Disorder
Phase 2Not yet recruitingKyle Greenway162026-12-012026-11-18
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Psilocybin, Cognitive Training - Alzheimer's Disease
Phase 2RecruitingNational Institute on Aging (NIA)2002026-11-252026-11-20
Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life
Psilocybin (Usona Institute) - Aging, Longevity
Phase 1RecruitingCharles Raison502026-11-162026-11-17

Showing 20 of 265. Sign in to see all of them.

Conditions studied

Depression (47)  ·  Depressive Disorder, Major (32)  ·  Depressive Disorder, Treatment-Resistant (26)  ·  Stress Disorders, Post-Traumatic (22)  ·  Alcoholism (19)  ·  Anxiety Disorders (16)  ·  Neoplasms (10)  ·  Opioid-Related Disorders (9)  ·  Obsessive-Compulsive Disorder (8)  ·  Substance-Related Disorders (7)  ·  Anorexia Nervosa (6)  ·  Chronic Pain (6)  ·  Depressive Disorder (6)  ·  Pain (5)  ·  Anhedonia (4)

Sponsors

Johns Hopkins University (29)  ·  Yale University (14)  ·  NYU Langone Health (9)  ·  University of Wisconsin, Madison (9)  ·  Centre for Addiction and Mental Health (8)  ·  COMPASS Pathways (7)  ·  University Hospital, Basel, Switzerland (6)  ·  Imperial College London (5)  ·  University of Calgary (5)  ·  University of Washington (5)  ·  University Health Network, Toronto (4)  ·  University of California, Los Angeles (4)  ·  University of Zurich (4)  ·  Washington University School of Medicine (4)  ·  Centre Hospitalier Universitaire de NÄ«mes (3)

Countries

United States (170)  ·  Canada (34)  ·  United Kingdom (15)  ·  Switzerland (11)  ·  Denmark (6)  ·  France (6)  ·  Ireland (4)  ·  Sweden (4)  ·  Czechia (3)  ·  Germany (3)  ·  Israel (3)  ·  Netherlands (3)  ·  Australia (2)  ·  Belgium (2)  ·  Brazil (2)

Top investigators

Charles Raison, MD (7)  ·  Frederick S Barrett, PhD (4)  ·  Roland R Griffiths, Ph.D. (4)  ·  Anthony Back, MD (3)  ·  Benjamin Kelmendi, MD (3)  ·  Ishrat Husain, MBBS, MD (3)  ·  Leah Mayo, PhD (3)  ·  Michael Bogenschutz, MD (3)  ·  Sandeep Nayak, MD (3)  ·  Scott Aaronson, MD (3)  ·  Stephen Ross, MD (3)  ·  Alan K Davis, PhD (2)  ·  Albert Garcia-Romeu, PhD (2)  ·  Anders Fink-Jensen, Professor (2)  ·  Anthony Bossis, PhD (2)

Results publications

PMID 17196053, PMID 20819978, PMID 21674151, PMID 24550805, PMID 25586396, PMID 27578767, PMID 27909164, PMID 27909165, PMID 28353056, PMID 28704354, PMID 29020861, PMID 29577509, PMID 29764303, PMID 29945469, PMID 31543078, PMID 31916890, PMID 32371500, PMID 33146667, PMID 33150319, PMID 33184743, PMID 33852780, PMID 33902087, PMID 33993135, PMID 34744825, PMID 34867525, PMID 35001856, PMID 35217796, PMID 35411074, PMID 35431912, PMID 36001306, PMID 36044208, PMID 36241352, PMID 36322843, PMID 36332827, PMID 36507738, PMID 36532184, PMID 36636296, PMID 36881769, PMID 37142308, PMID 37181888, PMID 37231080, PMID 37276086, PMID 37302533, PMID 37337526, PMID 37488291, PMID 37651119, PMID 38055270, PMID 38105655, PMID 38247730, PMID 38264632

NIH funding

R34AT013077 (2), 1DP2DA066200 (1), 1UG3DA062088-01 (1), 1UG3DA067126 (1), 2016 (1), 2017 (1), 2023 (1), 2025 (1), I01RD001520 (1), K23MH122777 (1), P30CA138292 (1), R01AA031417 (1), R01CA312541 (1), R01DA066452 (1), R01MH142698 (1)